Literature DB >> 10469641

Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist.

A C Pike1, A M Brzozowski, R E Hubbard, T Bonn, A G Thorsell, O Engström, J Ljunggren, J A Gustafsson, M Carlquist.   

Abstract

Oestrogens exert their physiological effects through two receptor subtypes. Here we report the three-dimensional structure of the oestrogen receptor beta isoform (ERbeta) ligand-binding domain (LBD) in the presence of the phyto-oestrogen genistein and the antagonist raloxifene. The overall structure of ERbeta-LBD is very similar to that previously reported for ERalpha. Each ligand interacts with a unique set of residues within the hormone-binding cavity and induces a distinct orientation in the AF-2 helix (H12). The bulky side chain of raloxifene protrudes from the cavity and physically prevents the alignment of H12 over the bound ligand. In contrast, genistein is completely buried within the hydrophobic core of the protein and binds in a manner similar to that observed for ER's endogenous hormone, 17beta-oestradiol. However, in the ERbeta-genistein complex, H12 does not adopt the distinctive 'agonist' position but, instead, lies in a similar orientation to that induced by ER antagonists. Such a sub-optimal alignment of the transactivation helix is consistent with genistein's partial agonist character in ERbeta and demonstrates how ER's transcriptional response to certain bound ligands is attenuated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469641      PMCID: PMC1171535          DOI: 10.1093/emboj/18.17.4608

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  168 in total

1.  Mass-spectrometric analysis of agonist-induced retinoic acid receptor gamma conformational change.

Authors:  Valerie J Peterson; Elisabeth Barofsky; Max L Deinzer; Marcia I Dawson; Kai-Chia Feng; Xiao-kun Zhang; Machender R Madduru; Mark Leid
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles.

Authors:  So-Jung Park; Irina Kufareva; Ruben Abagyan
Journal:  J Comput Aided Mol Des       Date:  2010-05-09       Impact factor: 3.686

3.  CoMFA and docking study of novel estrogen receptor subtype selective ligands.

Authors:  Peter Wolohan; David E Reichert
Journal:  J Comput Aided Mol Des       Date:  2003 May-Jun       Impact factor: 3.686

4.  Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways.

Authors:  Xiaodong Li; Jing Huang; Ping Yi; Robert A Bambara; Russell Hilf; Mesut Muyan
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

5.  Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage.

Authors:  Nicole R Bianco; Laura J Chaplin; Monica M Montano
Journal:  Biochem J       Date:  2005-01-01       Impact factor: 3.857

Review 6.  Structural and functional insights into nuclear receptor signaling.

Authors:  Lihua Jin; Yong Li
Journal:  Adv Drug Deliv Rev       Date:  2010-08-17       Impact factor: 15.470

7.  Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides.

Authors:  Manghong Zhu; Chen Zhang; Jerome C Nwachukwu; Sathish Srinivasan; Valerie Cavett; Yangfan Zheng; Kathryn E Carlson; Chune Dong; John A Katzenellenbogen; Kendall W Nettles; Hai-Bing Zhou
Journal:  Org Biomol Chem       Date:  2012-11-21       Impact factor: 3.876

8.  Soy isoflavones have an antiestrogenic effect and alter mammary promoter hypermethylation in healthy premenopausal women.

Authors:  Wenyi Qin; Weizhu Zhu; Huidong Shi; John E Hewett; Rachel L Ruhlen; Ruth S MacDonald; George E Rottinghaus; Yin-Chieh Chen; Edward R Sauter
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

Review 9.  Isoflavones and skeletal health: are these molecules ready for clinical application?

Authors:  S Migliaccio; J J B Anderson
Journal:  Osteoporos Int       Date:  2003-04-29       Impact factor: 4.507

10.  Biochanin A inhibits breast cancer tumor growth in a murine xenograft model.

Authors:  Young Jin Moon; Beom Soo Shin; Guohua An; Marilyn E Morris
Journal:  Pharm Res       Date:  2008-05-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.